Related Experiment Videos
Juvenile idiopathic arthritis: the paediatric perspective
Alison Jordan1, Janet E McDonagh
1Department of Adolescent Rheumatology, Birmingham Children's Hospital, Birmingham, UK.
Pediatric Radiology
|May 12, 2006
Summary
Paediatric rheumatology has advanced significantly, improving juvenile idiopathic arthritis (JIA) classification and treatment. Future efforts focus on early prognosis identification and optimizing long-term outcomes for young patients.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Clinical Medicine
Background:
- Paediatric rheumatology has seen rapid development over the past 30 years.
- Significant progress has been made in the classification and management of juvenile idiopathic arthritis (JIA).
Purpose of the Study:
- To review advances in paediatric rheumatology, focusing on juvenile idiopathic arthritis (JIA).
- To highlight current challenges and future directions in JIA management.
Main Methods:
- Literature review of advancements in paediatric rheumatology and JIA.
- Analysis of improvements in classification, international collaboration, and therapeutic agents.
Main Results:
- Enhanced international collaboration through disease registries and multicentre research.
- Development of new therapeutic agents leading to improved disease control and remission induction in many JIA patients.
Conclusions:
- Despite advances, significant morbidity persists in JIA across childhood, adolescence, and adulthood.
- Future challenges include early identification of poor prognosis, safe therapy administration, and optimizing outcomes during transition to adulthood.
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...